Mission Statement CTIWP
To understand and exploit the biological including immunological events occurring upon HSCT at large, and to implement modern cellular therapies based on cell and gene engineering approaches to improve transplantation outcomes. The CTIWP aims at fostering cellular therapy in Europe, through a continuous crosstalk between basic science findings, transplant immunobiology observations and implementation of cell therapy approaches to answer unmet medical needs. This year the CTIWP is delighted to welcome the STWF Scientific Community as a new Subcommittee of the WP1.

CALL FOR DATA

NK Cell Allo-Reactivity
PI’s: A. Velardi, L. Ruggeri
In collaboration with PDWP & ALWP
The role of donor vs. recipient NK cell allo-reactivity in haploidentical hematopoietic transplantation for AML and ALL
Donor-versus-recipient NK cell allo-reactivity is a key therapeutic element in the success of HLA haploptotype mismatched (“haploidentical”) HSCTs for acute myeloid leukemia. The role of NK cell allo-reactivity will be assessed separately in T cell depleted and T cell replete transplants in patients with 1) AML or ALL in any remission; and 2) AML or ALL in chemo-resistant relapse.

*Participating centres please send in your HLA-data and EXCEL file*

Immune Reconstitution Survey
PI: R. Greco
Aims: 1) To verify how frequently, and with which methods is Immunological monitoring performed in transplanted patients. 2) To generate Consensus guidelines of the European Group for Blood and Marrow Transplantation for monitoring post-transplant immune reconstitution
Presented in detail at oral session (room Les Goudes 1)
13: MRD, chimerism and immune reconstitution, Tuesday, March 28th, 4.30-6.00pm

*Please complete the survey; paper version available at EBMT booth*

MSC Survey
PI: F. Dazzi
Manufacturing of Mesenchymal Stromal Cells for the treatment of Graft-versus-Host Disease: a Survey within the European Society of Blood and Marrow Transplantation
Results of this survey are presented at the poster session: March 27th, poster #A173

Cellular Therapy Registry
This a joined effort with ADWP and IEWP
Due to an urgent need to register data on patients undergoing cellular therapy in Europe, the CTIWP is implementing an upgrade to the EBMT registry forms which will improve the EBMT ability to collect additional and high-quality clinical and biological information from patients undergoing standard HSCT alone or combined with HSCT.
EBMT is gearing up to be an actor of extended post-marketing surveillance for innovative cellular and gene therapy currently evaluated in clinical trials and approaching commercialization, as requested by competent authorities.

PLEASE JOIN … AND REGISTER YOUR PATIENTS!
The new form and manual are now available at www.ebmt.org in the following section:
Data Management > Registry structure > Data collection forms & manuals

2nd CTIWP Scientific Symposium
Following the success of the 1st CTIWP Scientific Symposium held in Milan in November 2015, the 2nd edition will take place in Leiden, NL, in January 2018. International experts will gather for in-depth discussions of the latest advances in the development of cellular and gene therapies with applications in the field of hematological diseases and solid tumors.
Look for detailed information in coming weeks.
Local and CTIWP organizing committee: Gerard Bos, Lotte Wieten, Fred Falkenburg, Jurgen Kubel, Chiara Bonini and Christian Chabannon.